Pharmaceuticals and Healthcare Reports 5EU Melanoma Market | Page 2

growth of the 5EU market is expected to be driven by increasing disease incident cases and the
launch of new regimens, such as label expansion of Yervoy into the first-line setting, BRAF/MEK
inhibitor combinations, anti-PD-1 immunotherapies, and the Yervoy/Opdivo combination. However,
Radiant Insights expects that the cost consciousness of the European healthcare systems, as well as
the difficulties in getting reimbursement approval in individual European countries, will limit the
growth of the melanoma branded market.
*This is an on-demand report and will be delivered within 24 hrs. (excluding weekends) of the
purchase.
Request a Sample Copy of This Report @
http://www.radiantinsights.com/research/melanoma-5eu-drug-forecast-and-market-
analysis-to-2023/request-sample
Scope
- Overview of Melanoma including epidemiology, etiology, symptoms, diagnosis, pathology and
treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on the key drugs in 5EU including product Melanomacription, safety and
efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top drugs in 5EU from 2013-2023.
- Analysis of the impact of key events as well the drivers and restraints affecting 5EU Melanoma
market.
Reasons To Buy
- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for
Melanoma.
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising
sales potential
- Make more informed business decisions from insightful and in-depth analysis of drug performance
- Obtain sales forecast for drugs from 2013-2023 in 5EU.
See More Reports of This Category by Radiant Insights @
http://www.radiantinsights.com/catalog/pharmaceuticals-and-healthcare
Follow Us: